Less than a year after the end of a PD-1 deal with Novartis, BeiGene is looking at new partnerships that could bring in new assets it could develop or commercialize, or out-license some of its substantial cancer pipeline.
In an interview with Endpoints News, BeiGene CEO John Oyler talked through…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
